Further personnel changes in the pharmaceutical industry
Ten post jest także dostępny w języku:
polski
In May, we already informed about two important personnel changes, and this is not the end! Mabion makes key changes related to the company’s management. The company appointed Krzysztof Kaczmarczyk to the position of the President of the Management Board. Moreover, from 2022, the European Union Pharmaceutical Group (PGEU) will have a new president.
Kaczmarczyk at the head of the Mabion company
On May 13, 2021, Mabion’s Supervisory Board decided to dismiss Dirk Kreder from the position of CEO. At the same time, Mabion appointed Krzysztof Kaczmarczyk to this position. Kaczmarczyk has extensive experience in the capital market, as in the years 2006-2020 he served as a member of the Supervisory Boards of over thirty companies listed on the WSE. Importantly, he also held this position at Mabion prior to becoming President of the Management Board. In his place, Mabion appointed Robert Konski, who in his career to date has worked for companies such as: Kulczyk Holding, PGE or Kruk among others.
It is worth mentioning that Kaczmarczyk served as Vice President of the Management Board for Strategy and Development at Emitel, the operator of the terrestrial radio and television network in Poland, from 2012 to 2015. Moreover, from 2016 to 2019 he worked as an advisor to the board of KGHM Polska Miedź. In his position as CEO of Mabion, his main task will be to effectively conduct the process of acquiring a strategic investor and to cooperate with the biotech company Novavax.
Mabion SA was established by four domestic pharmaceutical companies: Celon Pharma of Lomianki, Polfarmex of Kutno, IBSS Biomed of Krakow and Genexo of Warsaw. The company has been listed on the WSE since April 2013.
New president of the European Union Pharmaceutical Group
On 12 May 2021, the general meeting of the European Union Pharmaceutical Group (PGEU) took place in which decisions were made regarding structural changes. The key change is the appointment of a new president of PGEU. From 2022, the president of the organization will be performed by the Italian pharmacist Roberto Tobia, who is a member of the Federfarma federation. Federfarma represents over 90% of Italian owners of private pharmacies.
The European Union Pharmaceutical Group (PGEU) is the voice of the social pharmacy in Brussels. The main goal of PGEU is to increase the contribution of environmental pharmacists to European healthcare systems, society and individual patients.
